Food, Global Health 3 min

Fresh ammunition in the war on lice!

PRESS RELEASE - Lice are parasitic insects which cause a significant public health problem, affecting millions of people every year. While head lice may be the best-known members of this family, their cousins, body lice, are even more redoubtable. The human lice Pediculus humanus are the causative agent of pediculosis, an infestation characterised by intense itching of the scalp and body. Beyond the social impacts caused by these tenacious parasites, the physical consequences of their presence can be serious as body lice harbour bacteria that can cause severe illness. What is more, they are becoming increasingly resistant to treatment. A novel study led by researchers from INRAE and the University of Tours has revealed the ways in which various insecticides, already in use against other parasites, act on lice. The study, published on 18 February in PLoS Pathogens, provides insight into how these insecticides work and opens up new areas for manœuvre in the ongoing fight against lice.

Published on 19 February 2021

illustration Fresh ammunition in the war on lice!
© Flickr - Clémentine Gras

Human lice, Pediculus humanus, are cosmopolitan parasites that mostly attack the scalp and the skin. A significant risk to public health, lice affect millions of people each year and are proving increasingly resistant to treatment. To find a way round this resistance we need to develop new treatments. To this end, researchers from INRAE and the University of Tours have worked together to expand our knowledge of how certain anti-parasitic treatments currently on the market function and to determine which molecules are best-suited to the elimination of lice at each stage of their development.

From louse breeding to electrophysiology

For their study, the researchers used a laboratory-reared colony of body lice that was susceptible to insecticides. They tested the effectiveness of a number of products (already in use on other insects) on lice and their eggs (nits). Fipronil, ivermectin and lotilaner1 were high performers and were found to cause death in adult lice but to have no effect on nits. The study is also the first to have demonstrated the efficacy of lotilaner on lice. This product proved to be considerably more effective than the other insecticides tested, achieving a 100% success rate more quickly and at lower concentrations.

Alongside these tests, bioinformatic, molecular and electrophysiological investigations were carried out to identify the receptors for these insecticidal molecules. By cross-referencing their own data with those available for other insects, the researchers discovered two genes encoding the channels, Phh-GluCI and Phh-RDL, which mediate the inhibitory nerve signals in insects. Subsequently, the scientists demonstrated that these receptors were targeted by ivermectin and lotilaner.

 

The team’s results allow a better understanding of how anti-parasitic insecticides work and suggest that the class of compounds to which lotilaner belongs (isoxazolines) could be used as a new treatment against lice. The study opens up fresh strategic avenues in the field of human health, offering a way to work around any resistance to ivermectin in the battle against severe lice infestations.

 

1A veterinary medicine on the market  since 2017 under the name CredelioTM for use against ticks and fleas in dogs and cats.

A lice farm in the lab?

 

One of the resources available in INRAE’s ISP (infectiology and public health) research unit is its precious laboratory-bred louse colony. One of just four in the world, it was established following a donation of body lice from Professor K Y Mumcuoglu’s colony at the Hebrew University of Jerusalem. The lice have since been cared for by members of the ISP BioMAP team and the colony produces several thousand lice each year. They are used regularly to test products for over a dozen companies, making it possible to assess a product’s effects on both adult lice and nits. These trials are helpful in formulating more general remedies for lice infestations, since treatments that are effective for body lice frequently turn out to work for head lice as well.

 

 

Reference

Lamassiaude N, Toubate B, Neveu C, Charnet P, Dupuy C, Debierre-Grockiego F, Dimier-Poisson I, Charvet CL. The molecular targets of ivermectin and lotilaner in the human louse Pediculus humanus humanus: new prospects for the treatment of pediculosis. PLoS Pathogens, 2021; 17(2): e1008863. https://doi.org/10.1371/journal.ppat.1008863

 

PR_Fresh ammunition in the war on lice_19022021.pdfpdf - 897.07 KB

INRAE Press Office

Scientific contacts

Claude Charvet Research Unit for Infectiology and Public Health (ISP)

Isabelle Dimier-Poisson Research Unit for Infectiology and Public Health (ISP)

Centre

Division

Learn more

Agroecology

Phytopharmacovigilance: the effects of diamides on honey bees

Clorantraniliprole was granted a marketing authorisation by the European Union in 2014 as the first representative of a new class of insecticides: diamides. The effects of this active substance on domestic honey bees have been studied by scientists at INRA’s Research Unit for Bees and the Environment. The results of their work, published in Scientific Reports, have demonstrated long-lasting motor impairments affecting this pollinating insect, even after being exposed just once to a sublethal dose of chlorantraniliprole. This class of insecticides has also sparked questions with respect to human health, particularly in subjects who suffer from certain neuromuscular diseases of genetic origin.

23 January 2020

Food, Global Health

Two rare mutations responsible for the toxicity of treatment for scabies

PRESS RELEASE - Ivermectin is a drug that is widely used to treat parasitic diseases. Initially developed during the 1980s for veterinary use, it was then adapted to deal with human parasites in tropical countries. Considered to be safe in humans, it is now used to treat scabies and head lice. INRAE scientists working with clinicians and biologists at Toulouse and Montpellier University Hospitals have reported on a boy treated with ivermectin to prevent scabies who was found to present with rare mutations associated with its acute toxicity. Their findings were published on 20th August 2020 in the New England Journal of Medicine.

20 August 2020